Publications:
Our Research

Filter

Filter

Research Area
Technology
Resource type
Category
223 results found
Sep 27, 2024
Publication
Novavax led
Journal of Infection
COVID-19, Matrix-M® adjuvant
Immunogenicity and Safety of SARS-CoV-2 Recombinant Spike Protein Vaccine in South African People Living With and Without HIV-1 Infection: A Phase 2 Randomised Trial
Chijioke Bennett, Zaheer Hoosain, Anthonet Koen, et al.
Sep 26, 2024
Publication
Novavax included/third party
Clinical Infectious Diseases
COVID-19, Matrix-M® adjuvant
Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial
Fong Y, Dang L, Zhang B, et al.
Sep 3, 2024
Publication
Collaborative
The Journal of Infectious Diseases
COVID-19, Matrix-M® adjuvant
Association Between SARS-CoV-2 Viral Load and COVID-19 Vaccination in 4 Phase 3 Trials
Janes H, Fisher LH, Kee JJ, et al.
Aug 15, 2024
Publication
Collaborative
Clinical Infectious Diseases
COVID-19, Matrix-M® adjuvant
COVID-19 Vaccine Efficacy in Participants with Weakened Immune Systems From 4 Randomized Controlled Trials
Sherman AC, Tuan J, Cantos VD, et al.
Aug 15, 2024
Publication
Collaborative
Clinical Infectious Diseases
COVID-19, Matrix-M® adjuvant
COVID-19 vaccine efficacy in participants with weakened immune systems from four randomized-controlled trials
Sherman A, Tuan J, Cantos VD, et al.
Jul 19, 2024
Publication
Novavax led
Vaccines
COVID-19, Matrix-M® adjuvant
Reactogenicity Differences between Adjuvanted, Protein-Based and Messenger Ribonucleic Acid (mRNA)-Based COVID-19 Vaccines
Matthew D. Rousculp, Kelly Hollis, Ryan Ziemiecki, et al.
Jul 14, 2024
Publication
Novavax led
microorganisms
COVID-19, Matrix-M® adjuvant
Validation of a Pseudovirus Neutralization Assay for Severe Acute Respiratory Syndrome Coronavirus 2: A High-Throughput Method for the Evaluation of Vaccine Immunogenicity
Raj Kalkeri, Ph.D., Mingzhu Zhu, Ph.D., Shane Cloney-Clark B.Sc, et al.
Jul 5, 2024
Pre-print
Novavax led
medRxiv
COVID-19, Matrix-M® adjuvant
Short-Term Relative Effectiveness of Homologous NVX-CoV2373 and BNT162b2 COVID-19 Vaccinations in South Korea
Eunseon Gwak, Seung-Ah Choe, Erdenetuya Bolormaa, et al.
Jun 25, 2024
Pre-print
Novavax led
medRxiv
COVID-19, Matrix-M® adjuvant
Reactogenicity Differences between COVID-19 Vaccines: A Prospective Observational Study in the United States and Canada
Matthew D. Rousculp, Kelly Hollis, Ryan Ziemiecki, et al.
May 23, 2024
Publication
Novavax led
JAMA Network Open
COVID-19, Matrix-M® adjuvant
SARS-CoV-2 Viral Load in the Nasopharynx at Time of First Infection Among Unvaccinated Individuals A Secondary Cross-Protocol Analysis of 4 Randomized Trials
Fisher LH, Kee JJ, Liu A, et al.